Cargando…

Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis

BACKGROUND: Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs). Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment adherence vs daily medications. Although medication compliance can be poor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurel, Michelle H., Han, Yi, Stevens, Andrea L., Furtado, Aaron, Cox, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379584/ https://www.ncbi.nlm.nih.gov/pubmed/28372573 http://dx.doi.org/10.1186/s40360-017-0124-y

Ejemplares similares

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review
por: Heidarpour, Maryam, et al.
Publicado: (2019)

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs
por: Daniel, Charles P., et al.
Publicado: (2023)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
por: Kizilgul, Muhammed, et al.
Publicado: (2022)

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
por: Bianchi, Antonio, et al.
Publicado: (2013)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
por: Pita-Gutierrez, Francisco, et al.
Publicado: (2013)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
por: Shen, Ming, et al.
Publicado: (2018)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
por: O’Toole, Dermot, et al.
Publicado: (2022)

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
por: Adelman, Daphne T, et al.
Publicado: (2012)

Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”
por: Shen, Ming, et al.
Publicado: (2019)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

The Influence of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors
por: Chahid, Youssef, et al.
Publicado: (2023)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

A case of malignant insulinoma responsive to somatostatin analogs treatment
por: Caliri, Mariasmeralda, et al.
Publicado: (2018)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
por: Cella, David, et al.
Publicado: (2021)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
por: Fleseriu, Maria, et al.
Publicado: (2023)

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
por: Sala, E., et al.
Publicado: (2021)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ghqlvtulqji2kb2129b7vpkmok